Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Fibrillary Glomerulonephritis
NCT02197767Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2014
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in fibrillary glomerulonephritis (FGN), sponsored by Mayo Clinic. Primary endpoint: Change in 24 Hour Creatinine Clearance at Day 365. Started Nov 2014; status: completed.
02
Drugs
rituximab
03
Conditions
fibrillary glomerulonephritis (FGN)
Beyond the preview
Go deeper on NCT02197767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197767.